SWaN & Legend Venture Partners — 2026 Investments

1 investments dated 2026 · listed companies and verified rows first · show all

Georgiamunegeorgiamune.com inJul 2026SEC filingmedium confidence

Georgiamune is a biopharmaceutical company developing targeted immunomodulator drugs that activate or down-modulate immune signaling pathways to treat cancer and autoimmune diseases.

BiotechDeep TechHealthtechGaithersburg, US

Samir N. Khleif(Founder & CEO)inRamy Ibrahim(Chief Medical and Strategy Officer)inMikayel Mkrichyan(Senior Vice President of Science and Discovery)Sarah Sharman(Vice President of IP Legal Affairs)

BoardSean Parker(Director)Elena Viboch(Director)in

Board seat Fredrick D. Schaufeld· per SEC Form D · $131.9M raise · filed Aug 2026

Co-investorsCatalio Capital Management, LP General Catalyst HAWKTAIL Lauder Partners Prevail Venture Capital Alexandria +3 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.